NUCKS Inhibitors represent a specialized class of chemical compounds designed to interact with and modulate the activity of Nuclear Casein Kinase and Cyclin-dependent Kinase Substrate (NUCKS). NUCKS, also known as NUCKS1 or p120, is a multifunctional nuclear protein involved in various cellular processes, though it is not as extensively characterized as some other cellular proteins. Its roles encompass DNA binding, gene regulation, and involvement in DNA damage response. NUCKS is an enigmatic player in the cellular landscape, with its precise functions in many of these processes still under active investigation. Inhibitors developed for NUCKS are meticulously crafted to selectively target this protein, offering researchers a valuable tool to explore the specific molecular and functional contributions of NUCKS within the nucleus.
The design of NUCKS inhibitors emphasizes their selectivity, ensuring they interact exclusively with NUCKS without affecting other nuclear components or cellular processes. This selectivity is crucial for scientific research, as it permits the investigation of the exact functions and regulatory mechanisms governed by NUCKS. By employing NUCKS inhibitors, researchers can delve deeper into the molecular and genetic mechanisms associated with this nuclear protein, potentially uncovering its relevance to DNA replication, transcriptional regulation, and DNA damage repair. While the precise roles of NUCKS remain a subject of ongoing exploration, the study of NUCKS inhibitors opens new avenues for understanding the complexities of nuclear biology and the potential contributions of lesser-characterized proteins to various cellular processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
Targets BCR-ABL kinase, used for chronic myeloid leukemia by inhibiting the abnormal tyrosine kinase activity of BCR-ABL. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibits multiple kinases, including Raf, VEGFR, and PDGFR, used for renal cell carcinoma by disrupting tumor cell signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, commonly used for non-small cell lung cancer. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Targets multiple receptor tyrosine kinases like VEGFR, PDGFR, and KIT. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Inhibits both EGFR and HER2 kinases. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Targets BCR-ABL and SRC kinases, prescribed for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Selectively inhibits the mutant BRAF kinase, used for melanoma with BRAF V600E mutation. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Targets BCR-ABL kinase, similar to imatinib but used in cases of imatinib resistance in chronic myeloid leukemia. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Targets multiple kinases including VEGFR, PDGFR, and FGFR, approved for colorectal cancer and advanced gastrointestinal stromal tumors. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $172.00 $964.00 | 2 | |
Effective against multiple BCR-ABL mutations, particularly T315I, in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. | ||||||